68291-97-4
68291-97-4 structure
- Name: Zonisamide
- Chemical Name: zonisamide
- CAS Number: 68291-97-4
- Molecular Formula: C8H8N2O3S
- Molecular Weight: 212.226
- Catalog: API Nervous system medication Antiepileptic and anticonvulsant
- Create Date: 2018-03-10 08:00:00
- Modify Date: 2026-07-17 10:28:15
-
Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.Target: Calcium channel inhibitor; Sodium channel inhibitorZonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. It has shown activity in various animal models of epilepsy, and although a detailed mode of action awaits clarification it appears to block the propagation/spread of seizure discharges and to suppress the epileptogenic focus [1].Zonisamide 500 mg/day was significantly superior to placebo in reducing the frequency of complex partial seizures (-51% versus -16%), all partial seizures and all seizures, with dose-dependent benefit provided over a 100-500 mg/day dose range. Supporting trials have confirmed significant increases in reduction in median seizure frequency (up to 41%) and responder rates (35-42%) compared with placebo following zonisamide 400-600 mg/day, enabling 20-27% of patients to attain >or=75% reduction in seizure frequency [2].Clinical indications: Epilepsy; Lewy body dementia; Parkinsons diseaseToxicity: Anorexia; Somnolence; Dizziness; Irritability; Confusional state; Depression; Diplopia; Memory impairment
| Name | zonisamide |
|---|---|
| Synonyms |
Excegran
Zonisamide, >= 3-(sulfamoylmethyl)-1,2-benzisoxazole Zonisamide (AD 1-(1,2-Benzisoxazol-3-yl)methansulfonamid AD810, CI912 Zonisamide 13C6 1-(1,2-Benzoxazol-3-yl)methanesulphonamide ZONISAMIDE 1,2-BENZISOXAZOLE-3-METHANESULFONAMIDE MFCD00865316 Zonean Zonisamide 1.0 mg/ml in Methanol Zonisamide, Non-selective Na+ / Ca2+ channel blocker Zonisamide, 10 mM in DMSO D4,15N-Zonisamide 2H4,15N]-Zonisamide 1-(1,2-benzisoxazol-3-yl)methanesulfonamide ad-810 1,2-benzoxazol-3-ylmethanesulfonamide Zonisamide (mM/ml), Na+ / Ca2+ channel blocker ZON Zonisamide solution pd110843 ZonisamideQ: What is Zonisamide Q: What is the CAS Number of Zonisamide Q: What is the storage condition of Zonisamide Q: What e the applications of Zonisamide indoxazen-3-ylmethanesulfonamide (1,2-Benzisoxazol-3-yl)methanesulfonamide 3-sulfamoylmethyl-1,2-benzisoxazole 1-(1,2-benzisoxazol-3-yl)méthanesulfonamide 3-sulfamoyl-methyl-1,2-benzisoxazol Zonisamide in methanol Zonisamide - Bio-X BENZO[D]ISOXAZOL-3-YL-METHANESULFONAMIDE Zonisamide //BP TIANFU-CHEM Zonisamide Zonegran exceglan 1-(1,2-Benzoxazol-3-yl)methanesulfonamide ZonisaMide Analogue: 5-Fluoro-3-sulfaMoyl Methyl-1,2-benzisoxazole Excemide excegram exceam 1,2-BENZISOXAZOLE-3-METHANESULFONATE, SODIUM SALT Zonisamide, 1.0 mg/mL Excean EINECS 200-659-6 Zonisamide (mM/ml) Zoniamide 1,2-Benzisoxazole-3-methanesulfonamide ci-912 |
| Description | Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.Target: Calcium channel inhibitor; Sodium channel inhibitorZonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. It has shown activity in various animal models of epilepsy, and although a detailed mode of action awaits clarification it appears to block the propagation/spread of seizure discharges and to suppress the epileptogenic focus [1].Zonisamide 500 mg/day was significantly superior to placebo in reducing the frequency of complex partial seizures (-51% versus -16%), all partial seizures and all seizures, with dose-dependent benefit provided over a 100-500 mg/day dose range. Supporting trials have confirmed significant increases in reduction in median seizure frequency (up to 41%) and responder rates (35-42%) compared with placebo following zonisamide 400-600 mg/day, enabling 20-27% of patients to attain >or=75% reduction in seizure frequency [2].Clinical indications: Epilepsy; Lewy body dementia; Parkinsons diseaseToxicity: Anorexia; Somnolence; Dizziness; Irritability; Confusional state; Depression; Diplopia; Memory impairment |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 457.2±47.0 °C at 760 mmHg |
| Melting Point | 275°C dec. |
| Molecular Formula | C8H8N2O3S |
| Molecular Weight | 212.226 |
| Flash Point | 230.3±29.3 °C |
| Exact Mass | 212.025558 |
| PSA | 94.57000 |
| LogP | -0.10 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.656 |
| Water Solubility | H2O: >5 mg/mL, soluble |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Hazard Codes | Xn |
| Risk Phrases | R22 |
| Safety Phrases | 7-16-36/37-45 |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| HS Code | 2935009090 |
|
~89%
68291-97-4 |
| Literature: WO2007/16208 A2, ; Page/Page column 16-17 ; |
|
~75%
68291-97-4 |
| Literature: US2006/9644 A1, ; Page/Page column 10 ; |
|
~86%
68291-97-4 |
| Literature: US2004/14983 A1, ; Page 4-5 ; |
|
~%
68291-97-4 |
| Literature: US2007/66830 A1, ; Page/Page column 5 ; |
| Precursor 3 | |
|---|---|
| DownStream 5 | |
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |